AMADIX 

Early cancer detection in blood, before the symptoms appear

OWNER

LUCIA REINOSO (See Profile)


Sector

Oncology

Stage

Development, market readiness, clinical trial

Country

España


Pipeline of 3 blood-based tests for early cancer detection, backed by solid science and strong patent protection

1 product (Colofast, for early colon cancer detection in blood) to be commercialized in the coming months

Highly specialized team, with an International Advisory Board (USA, EU and Israel).

Top level Scientific Committee of Gastroenterologists from 5 regions.

South Summit 2018 global winner.Awarded as a disruptive company by European Commission (Seal of Excellence, Nov 2020)

IP Type Status Time Countries Link Coverage
Patent Approved 2032
  • Australia
  • Belgium
  • Canada
  • Denmark
  • Finland
  • France
  • Germany
  • Italy
  • Japan
  • Netherlands
  • Russia
  • South Korea
  • Spain
  • Switzerland
  • United Kingdom
 

Patent link

PLASMA microRNAS FOR THE DETECTION OF EARLY COLORECTAL CANCERPLASMA microRNAS FOR THE DETECTION OF EARLY COLORECTAL CANCER
PCT/IB2012/003035
The present invention relates in general to the field of colorectal cancer detection, and more particularly, to plasma microRNAs for the detection of early Colorectal Cancer. Specifically, the present invention includes methods, kits and biomarkers for diagnosing or detecting colorectal neoplasia in a human subject comprising the steps of: A method for diagnosing or detecting colorectal neoplasia in a human subject comprising the steps of: obtaining one or more biological samples from the subject suspected of suffering from colorectal neoplasia; measuring an overall expression pattern or level of one or more microRNAs obtained from the one or more biological samples of the subject; and comparing the overall expression pattern of the one or more microRNAs from the biological sample of the subject suspected of suffering from colorectal neoplasia with the overall expression pattern of the one or more microRNAs from a biological sample of a normal subject, wherein the normal subject is a healthy subject not suffering from colorectal neoplasia.

IP Type Status Time Countries Link Coverage
Patent Approved 2032
  • Australia
  • Belgium
  • Canada
  • Denmark
  • Finland
  • France
  • Germany
  • Italy
  • Japan
  • Netherlands
  • Russia
  • South Korea
  • Spain
  • Switzerland
  • United Kingdom
https://https://patentscope.wipo.int/search/es/detail.jsf?docId=WO2013093635&_cid=P11-KNH83D-85980-1 Title: PLASMA microRNAS FOR THE DETECTION OF EARLY COLORECTAL CANCER
Application number: PCT/IB2012/003035
Granted: Europe (validated in: Germany, France, Spain, Italy, Denmark, Greece, United Kingdom, Ireland, Luxemburg, Swedish, Switzerland, Netherlands, Portugal, Poland, Romania, Hungary, Finland, Norway, and Belgium), Australia, Japan, South Korea, Mexico, Russia.
Pending: India, United States and China
Life extends: Until 2032
Brief description: Improve the protection of different embodiments comprised in the above parent application.

IP Type Status Time Countries Link Coverage
Patent Approved 2037
  • Austria
  • Belgium
  • Denmark
  • Finland
  • France
  • Germany
  • Italy
  • Netherlands
  • Spain
  • Switzerland
  • USA
  • United Kingdom
https://patentscope.wipo.int/search/es/detail.jsf?docId=WO2018096154&_cid=P11-KNH84Y-86793-1 Title: VITRO METHOD FOR IDENTIFYING COLORECTAL ADENOMAS OR COLORECTAL CANCER
Application number: PCT/EP2017/080560
Pending: Europe and United States
Life extends: Until 2037
Brief description: The present invention can be included in the field of personalized medicine, wherein specific biomarkers are used for identifying a given disease or disorder. Specifically, some microRNAs (also named miRNAs or miR-) are used in the present invention for identifying human subjects at risk of developing colorectal cancer (CRC) and/or colorectal adenomas (CA), preferably advanced colorectal adenomas (AA).

IP Type Status Time Countries Link Coverage
Patent Pending
  • Spain
https://patentscope.wipo.int/search/es/detail.jsf?docId=WO2020178172&_cid=P11-KNH85J-87052-1 // Title: PROTEIN SIGNATURE FOR THE DIAGNOSIS OF COLORECTAL CANCER AND/OR PRECANCEROUS STAGE THEREO
Application number: PCT/EP2020/055277
Pending: It is not yet extended into national phases. It is being examined in the international phase.
Life extends: Until 2040
Brief description: The present invention refers to an in vitro method for diagnosing, identifying or screening human subjects at risk of suffering from colorectal cancer and/or advanced colorectal adenomas, departing from the concentration level of protein biomarkers isolated from minimally-invasive samples such as blood, serum or plasma. The method of the invention offers high sensitivity and specificity, which means that it is a strong and cost-effective method for the detection of both colorectal cancer and colorectal adenomas.

IP Type Status Time Countries Link Coverage
Patent Pending
  • Spain
http://www.amadix.com Title: PROTEIN SIGNATURE FOR THE DIAGNOSIS/PROGNOSIS OF COLORECTAL CANCER AND/OR PRE-CANCEROUS STAGE
Application number: EP20382204.4
Status: This patent is going to be withdrawn soon. It has been extended together with the following patent into the PCT phase.
Patenscope link: Not publish yet

IP Type Status Time Countries Link Coverage
Patent Pending
  • Spain
http://www.amadix.com Title: PROTEIN SIGNATURE FOR THE DIAGNOSIS/PROGNOSIS OF COLORECTAL CANCER AND/OR PRE-CANCEROUS STAGE
Application number: EP20382205.1
Status: This patent is going to be withdrawn soon. It has been extended together with the following patent into the PCT phase
Patenscope link: Not publish yet

IP Type Status Time Countries Link Coverage
Patent Pending
  • Spain
http://www.amadix.com Title: PROTEIN SIGNATURE FOR SCREENING GENERAL POPULATION FOR COLORECTAL CANCER AND/OR PRECANCEROUS STAGE THEREOF
Application number: PCT/EP2021/056984
Status: This patent has been filled in March 2021. Its aim is to extend into the PCT phase both EP patents above. Currently, this patent is being examined into the international phase.
Life extends: Until 2041
Brief description: The present invention refers to an in vitro method for screening general population for colorectal cancer and/or advanced colorectal adenomas, departing from the concentration level of protein biomarkers isolated from minimally-invasive samples such as blood, serum or plasma. The method of the invention offers high sensitivity and specificity, which means that it is a strong and cost-effective method for the detection of both colorectal cancer and colorectal adenomas
Patenscope link: Not publish yet

IP Type Status Time Countries Link Coverage
Patent Approved 2033 years
  • Belgium
  • Denmark
  • Finland
  • France
  • Germany
  • Italy
  • Netherlands
  • Spain
  • Switzerland
  • USA
  • United Kingdom
https://patentscope.wipo.int/search/es/detail.jsf?docId=WO2013143940&_cid=P11-KNH87A-87898-1 Title: NEW LUNG CANCER MOLECULAR MARKERS
Application number: PCT/EP2013/055823
Granted: Europe (validated in: Germany, France, Spain, Italy, Denmark, Greece, Czech Republic, United Kingdom, Ireland, Luxemburg, Swedish, Switzerland, Netherlands, Portugal, Poland, Romania, Hungary, Finland, Norway, Belgium, Turkey and Iceland) and United States
Life extends: 2033
Brief description: The invention provides a method of diagnosis and/or prognosis of lung cancer, the method comprising the steps of: (a) determining the level of a C4 activation fragment in a test sample, and (b) comparing the level of the test sample with the level of a C4 activation fragment detected in a control sample, wherein if the level of C4 activation fragment is higher than the level in a reference control, it is indicative that the subject suffers lung cancer or has a bad prognosis. The present invention further provides methods for determining the risk of suffering from lung cancer as well as for deciding whether to initiate a medical regimen and to determine the efficacy of said medical regimen, based on the determination of a C4 activation fragment. C4 activation fragment, used as marker, confers high sensitivity and specificity to the methods object of the invention.

IP Type Status Time Countries Link Coverage
Patent Approved 2038 years
  • Australia
  • Canada
  • China
  • USA
https://patentscope.wipo.int/search/es/detail.jsf?docId=WO2017140651&_cid=P11-KNH87V-88217-1 Title: IN VITRO METHOD FOR THE DIAGNOSIS OF LUNG CANCER
Application number: PCT/EP2017/053234
Pending: Australia, Canada, China, United States and Europe (in Europe is going to be granted this year)
Life extends: 2038
Brief description: The present invention is generally related to diagnostic assays. In particular, the present invention refers to the use of at least C4c fragment as diagnostic and prognostic lung cancer marker. C4c fragment can also be useful to estimate lung cancer risk and to decide whether a medical regimen has to be initiated and to determine whether the medical regimen initiated is efficient.

IP Type Status Time Countries Link Coverage
Patent Pending 2037 years
  • Spain
https://patentscope.wipo.int/search/es/detail.jsf?docId=WO2017186588&_cid=P11-KNH88M-88563-1 Title: IN VITRO METHOD FOR IDENTIFYING PANCREATIC CANCER OR INTRADUCTAL PAPILLARY MUCINOUS NEOPLASM OF THE PANCREAS
Application number: PCT/EP2017/059498
Pending: China, United States (is going to be granted this year), Europe (is in validating phase)
Life extends: Until 2037
Brief description: The present invention can be included in the field of personalized medicine, wherein specific biomarkers are used for identifying a given disease or disorder. Specifically, some microRNAs (also named miRNAs or miR-) are used in the present invention for identifying human subjects at risk of developing pancreatic cancer or intraductal papillary mucinous neoplasm of the pancreas (IPMN), preferably pancreatic ductal adenocarcinoma (PDAC).

IP Type Status Time Countries Link Coverage
Trademark Approved 10 years
  • Spain
https://www.amadix.com COLOCEL
Type: Denominative trademark. Class 5, 35 and 44
Registered number: 018304044 (20/01/2021)
Granted: Europe
Pending: USA, Brazil, China, Japan, Canada, United Kingdom, India

IP Type Status Time Countries Link Coverage
Trademark Approved 10 years
  • Spain
https://www.amadix.com PREVECOL
Type: Denominative trademark. Class 5, 35 and 44
Registered number:018304045 (20/01/2021)
Granted: Europe
Pending: USA, Brazil, China, Japan, Canada, United Kingdom, India

IP Type Status Time Countries Link Coverage
Trademark Approved 10 years
  • Spain
https://www.amadix.com DIAGNOLUNG
Type: Denominative trademark. Class 5, 35 and 44
Registered number: 3.695.398 (07/05/2018)
Granted: Spain

IP Type Status Time Countries Link Coverage
Trademark Approved 10 years
  • Spain
https://www.amadix.com PANCREDIX
Type: Denominative trademark. Class 5, 35 and 44
Registered number: 3.695.405 (07/05/2018)
Granted: Spain

This information is confidential, do not share or copy.

Under evaluation at least till: 17th May

If you want to have more information or you want to review the project, you have to login or register

KEEP REVIEWING

©2021 BioExpert Network

About cookies

This website uses cookies to give you the best user experience. If you continue browsing you are giving your consent for the acceptance of those cookies and the acceptance of our cookies policy.

If you continue to browse and use this website you are agreeing to comply with and be bound by the following Terms of Use

ACEPTAR
Aviso de cookies

Log in with your credentials

or    

Forgot your details?

Create Account

Skip to toolbar